New psoriasis pill enters early human safety trials
NCT ID NCT07038720
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new tablet called UA026 to see if it is safe and how the body processes it. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The study is split into four parts to check different doses and the effect of food.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hangzhou First People's Hospital
RECRUITINGHangzhou, Zhejiang, 310006, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection clear psoriasis when other biologics fail?
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a Once-Daily cream tame psoriasis in toddlers?
- First look: can a new drug candidate pass early safety tests in humans?